Scholz S, Koerber F, Meszaros K, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37(1):1692-1701.INTRODUCTION: Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany. METHOD: A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase o...
Abstract Background Meningococcal meningitis (MM) is known to be responsible of high cost for the Pu...
AbstractBexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Eur...
OBJECTIVE: Recently, a vaccine with the capacity to protect against serogroup B meningococcal (MenB)...
Introduction: Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and ...
Gruhn S, Witte J, Greiner W, et al. Epidemiology and economic burden of meningococcal disease in Ger...
Scholz S, Schwarz M, Beck E, et al. Public Health Impact and Cost-Effectiveness Analysis of Routine ...
Background: Invasive meningococcal disease remains a public health concern because of its rapid onse...
Introduction: Invasive meningococcal disease (IMD) is an uncommon but life-threatening infectious di...
BACKGROUND: Meningococcal meningitis (MM) is known to be responsible of high cost for the Public Hea...
BACKGROUND: Meningococcal meningitis (MM) is known to be responsible of high cost for the Public Hea...
Nina Gustafsson,1 Sandra Elkjær Stallknecht,1 Mette Skovdal,2 Peter Bo Poulsen,3 Lars Ø...
AbstractInvasive meningococcal disease remains a substantial global public health burden despite bei...
SummaryInvasive meningococcal disease (IMD) is life-threatening and can result in severe sequelae. I...
BACKGROUND: Several countries consider the implementation of a meningococcal serogroup B vaccine for...
Bexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Europe in J...
Abstract Background Meningococcal meningitis (MM) is known to be responsible of high cost for the Pu...
AbstractBexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Eur...
OBJECTIVE: Recently, a vaccine with the capacity to protect against serogroup B meningococcal (MenB)...
Introduction: Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and ...
Gruhn S, Witte J, Greiner W, et al. Epidemiology and economic burden of meningococcal disease in Ger...
Scholz S, Schwarz M, Beck E, et al. Public Health Impact and Cost-Effectiveness Analysis of Routine ...
Background: Invasive meningococcal disease remains a public health concern because of its rapid onse...
Introduction: Invasive meningococcal disease (IMD) is an uncommon but life-threatening infectious di...
BACKGROUND: Meningococcal meningitis (MM) is known to be responsible of high cost for the Public Hea...
BACKGROUND: Meningococcal meningitis (MM) is known to be responsible of high cost for the Public Hea...
Nina Gustafsson,1 Sandra Elkjær Stallknecht,1 Mette Skovdal,2 Peter Bo Poulsen,3 Lars Ø...
AbstractInvasive meningococcal disease remains a substantial global public health burden despite bei...
SummaryInvasive meningococcal disease (IMD) is life-threatening and can result in severe sequelae. I...
BACKGROUND: Several countries consider the implementation of a meningococcal serogroup B vaccine for...
Bexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Europe in J...
Abstract Background Meningococcal meningitis (MM) is known to be responsible of high cost for the Pu...
AbstractBexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Eur...
OBJECTIVE: Recently, a vaccine with the capacity to protect against serogroup B meningococcal (MenB)...